Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald L Denardo

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RITSally J DeNardo, Gerald L DeNardo, A Yuan, et al.
International Journal of Oncology|September 6, 2007
Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphomaGerald L DeNardo, Saphon Hok, Arutselvan Van Natarajan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibodyCarol M Richman, Sally J Denardo, Robert T O'Donnell, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RITSally J DeNardo, Gerald L DeNardo, A Yuan, et al.
International Journal of Oncology|September 6, 2007
Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphomaGerald L DeNardo, Saphon Hok, Arutselvan Van Natarajan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibodyCarol M Richman, Sally J Denardo, Robert T O'Donnell, et al.
Pageof 7